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Abstract
Background: In the postgenomic era, high throughput protein expression and protein microarray
technologies have progressed markedly permitting screening of therapeutic reagents and discovery
of novel protein functions. Hexa-histidine is one of the most commonly used fusion tags for protein
expression due to its small size and convenient purification via immobilized metal ion affinity
chromatography (IMAC). This purification process has been adapted to the protein microarray
format, but the quality of in situ His-tagged protein purification on slides has not been systematically
evaluated. We established methods to determine the level of purification of such proteins on metal
chelate-modified slide surfaces. Optimized in situ purification of His-tagged recombinant proteins
has the potential to become the new gold standard for cost-effective generation of high-quality and
high-density protein microarrays.
Results: Two slide surfaces were examined, chelated Cu2+ slides suspended on a polyethylene
glycol (PEG) coating and chelated Ni2+ slides immobilized on a support without PEG coating. Using
PEG-coated chelated Cu2+ slides, consistently higher purities of recombinant proteins were
measured. An optimized wash buffer (PBST) composed of 10 mM phosphate buffer, 2.7 mM KCl,
140 mM NaCl and 0.05% Tween 20, pH 7.4, further improved protein purity levels. Using
Escherichia coli cell lysates expressing 90 recombinant Streptococcus pneumoniae proteins, 73
proteins were successfully immobilized, and 66 proteins were in situ purified with greater than 90%
purity. We identified several antigens among the in situ-purified proteins via assays with anti-S.
pneumoniae rabbit antibodies and a human patient antiserum, as a demonstration project of large
scale microarray-based immunoproteomics profiling. The methodology is compatible with higher
throughput formats of in vivo protein expression, eliminates the need for resin-based purification
and circumvents protein solubility and denaturation problems caused by buffer exchange steps and
freeze-thaw cycles, which are associated with resin-based purification, intermittent protein storage
and deposition on microarrays.
Conclusion: An optimized platform for in situ protein purification on microarray slides using His-
tagged recombinant proteins is a desirable tool for the screening of novel protein functions and
protein-protein interactions. In the context of immunoproteomics, such protein microarrays are
complimentary to approaches using non-recombinant methods to discover and characterize
bacterial antigens.
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Background
Sharp increases in the efficiency of DNA sequencing tech-
nology, coupled with dramatic decreases in cost have led
to very large quantities of DNA sequences to be deposited
into public databases. The number of complete genomes
continues to grow. More recently microbial DNA
sequences were derived from the environment and those
living in the context of the human host. Taken together
the numbers of genes of unknown function as well as
those without experimental confirmation grow at unprec-
edented rates. These advances have generated a strong
need for the development of very high throughput meth-
odologies with the capacity to characterize protein func-
tions in a highly parallel manner.
In the post-genomic era, highly parallel functional analy-
sis of proteins including hypothetical and conserved
hypothetical proteins has emerged as a major research
interest. Protein microarrays represent one of the most
powerful tools in this context [1-4]. Technical approaches
for protein microarrays have benefitted from its predeces-
sor, DNA microarray technology. Protein microarrays are
designed for high throughput analysis of proteins using
very small quantities of purified proteins [5]. Various pro-
tein microarray platforms have been developed, not only
for screening antibodies and antigens but also for discov-
ery of novel enzymes and enzymatic activities, protein-lig-
and, protein-nucleic acid and protein-protein interactions
[6-11]. Immunoproteomic analyses, that assess antibody-
antigen interactions, are among the most established
microarray applications [12-15]. Theses assays have the
potential to impact the field of infectious disease diagnos-
tics and greatly facilitate the design of subunit vaccines
[12,14]. The development of microarray applications for
the functional characterization of proteins of unknown or
unproven function continues to be a major challenge [15-
18].
The generation and immobilization of pure protein rea-
gents are critical to the quality of protein microarrays.
Many high throughput protein production platforms have
been reported [19-25]. Proteins are typically overex-
pressed in a heterologous host system (E. coli) and puri-
fied via affinity chromatography to fusion tags associated
with the recombinant proteins. A recently introduced
approach is based on highly parallel in vitro transcription
and translation using cellular extracts [26-28]. While pow-
erful, the difficulty with column based recombinant pro-
tein purification is relate to reduced throughput potential
and low protein stability and solubility of proteins during
pre-immobilization processing steps. The in vitro tran-
scription and translation approach is relatively expensive
and requires slide surfaces suitable for the immobilization
of DNA and proteins. Recently, the technology has
improved in efficiency and made significant studies with
regard to long term instability issues of proteins prior to
immobilization [9,29-31]. An in situ expression and puri-
fication method for GST-tagged proteins was reported by
Ramanchandran et al. [9,32].
On-chip purification of recombinant His-tagged proteins
on metal chelate affinity surface chips has been described
[31,33-35]. The quality of the on-chip purification
method has not been systematically tested. Moreover, a
major concern is that microarray chip surfaces allow non-
specific binding of endogenous cellular proteins. To
address these issues, double His-tagged fusion proteins
permitting more stringent purification conditions were
introduced [33,36].
Recently, we developed a high throughput His-tagged pro-
tein production pipeline in E. coli, based on the Gateway
cloning and expression system [24]. Here, we report a
platform that combines recombinant protein expression
in E. coli with in situ protein purification using a chip sur-
face with a low propensity to bind proteins non-specifi-
cally. We compare the quality of the resulting protein
microarray with that of a conventional metal chelate sur-
face and assess purity and recognition of the proteins by
serum antibodies.
Results and Discussion
Technical approach for in situ protein purification on 
metal chelate surface microarray slides
In situ protein purification on metal chelate chips syn-
chronizes protein purification and immobilization signif-
icantly reduces time, effort and cost of post-protein
expression processes, and generates high quality protein
microarray chips reproducibly. The approach we present
here can be combined with any expression system that
yields fusion proteins with an N- or C-terminal hexa-his-
tidine tag (His-tag). The same source set of expressed pro-
teins allows routine reproduction of identical protein
microarray chips. Both the microarray replicates and aliq-
uots of cells expressing the recombinant proteins can be
stored long-term without major concerns about the qual-
ity of the assays performed subsequently. This setup cir-
cumvents the problems caused by the long-term storage of
purified proteins, which include protein degradation, pre-
cipitation and aggregation. Buffer exchange of purified
and stored proteins at -80°C is not required. A flow dia-
gram for in situ protein purification from E. coli cell cul-
tures is shown in Figure 1. Recombinant proteins were
expressed in E. coli in 96-well block. Cell cultures were
divided into aliquots in 96-well plates and stored as cell
pellets at -80°C. The cell aliquots were subjected to lysis
followed by in situ purification and immobilization of
proteins via specific interactions of His-tagged proteins
with a slide surface chelated with either Ni2+ or Cu2+ (Fig-
ure 1B). High affinity interactions allow relatively strin-BMC Biotechnology 2009, 9:72 http://www.biomedcentral.com/1472-6750/9/72
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gent wash steps in which the majority of weakly bound
proteins are removed. Protein microarrays are stored at
4°C or used directly.
Optimization of in situ protein purification
Purity and quantity of in situ purified recombinant pro-
teins are highly dependent on a number of factors, includ-
ing the slide surface chemistry, solutions used for printing
slides and washing steps, the relative concentration of
recombinant proteins to host endogenous proteins,
recombinant protein solubility and the ambient humidity
during immobilization. There are two different types of
protein impurities, one related to non-specific binding
and the other caused by competitive binding. Non-spe-
cific interactions of endogenous E. coli proteins with a
metal chelate surface depend primarily on the chemistry
of the support surface. These impurities can be reduced or
eliminated using effective wash steps. In the context of
His-tagged proteins, competitive binding is often linked
to histidine-rich E. coli proteins such as the FKBP-type
Schematic of in situ purification of His-tagged proteins on protein microarray slides Figure 1
Schematic of in situ purification of His-tagged proteins on protein microarray slides. A) Flow diagram from recom-
binant protein expression to in situ purification and protein microarray. Cells were cultured in 1 mL 2xYT media in a 96-well 
block and the target proteins were overexpressed by adding IPTG at O.D.600 nm = 0.7–0.9. After induction, the cells were 
divided into several 96-well plates, and the cell pellets were stored at -20°C. The cell pellets were resuspended, and lysed. Sol-
uble fractions of lysates were subjected to in situ purification. Metal ions, either Ni2+ or Cu2+, were attached to the surface of a 
chip with a chelate structure. The chip surface was blocked with PBS buffer containing 5 mM imidazole and 3% dry milk, and 
the E. coli endogenous proteins were washed off with PBST, pH 7.4. The chips can be either stored or applied for protein 
microarray application directly. B) Scheme of selective immobilization of recombinant proteins. Approximately 50 nL of each 
soluble fraction of cell lysates was spotted on the metal ion (Ni2+ or Cu2+) chelated chip. His-tagged recombinant proteins 
were immobilized by binding tightly to the metal chelate. The endogenous E. coli proteins were washed with PBS containing 
0.05% Tween 20.
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peptidyl-prolyl-cis-trans-isomerase SlyD. Such impurities
cannot be eliminated easily and are independent on the
immobilization support. The higher an expression level of
a recombinant protein, the lower the competitive binding
effect of host endogenous proteins. In this study, we
examined wash buffers to minimize protein impurities
resulting from non-specific binding.
Two His-tagged recombinant proteins, the E. coli Lac
repressor (LacI) and the S. pneumoniae GTP cyclohydro-
lase I (FolE) were used to determine the optimum buffers
for printing and washing on two commercially available
slide supports. The first solid support binds a His-tag
using Ni2+ chelated by nitrilotriacetic acid (Ni2+/NTA) and
the second using Cu2+ by iminodiacetic acid groups on a
polyethylene glycol coated surface (Cu2+/IDA/PEG). We
used a quantitative approach to discern specific binding of
His-tagged proteins to the reactive surface from non-spe-
cific binding of endogenous E. coli proteins. The relative
quantity of immobilized His-tagged recombinant pro-
teins was measured with an Alexa Fluor 555 conjugated
anti-His-tag antibody, and the impurities were measured
using a rabbit anti-E. coli antibody derived with a mixture
of the E. coli serotypes O and K. The antibody-antigen
reactions were visualized using an ATTO 550 conjugate to
anti-rabbit or anti-human IgG as a secondary antibody.
Relative purities of immobilized His-tagged proteins on
the slides were estimated using the following equation.
The calculated relative purities were used as criteria to
define optimal conditions for in situ purification. Instead
of using two-channel detection method, one-channel
detection method for His-tagged proteins and E. coli
endogenous protein contaminants on a 2-pad slide sys-
tem was used to eliminate the mutual inferences of two
antibody interactions to the immobilized proteins and to
keep the same background in scanning. Considering the
fluorescence brightness of Alexa Fluor 555 and ATTO 550,
we estimate that the true level of purity of the immobi-
lized recombinant proteins is greater than the relative
purity measured according to Equation 1. The fluores-
cence brightness, which is a product of an extinction coef-
ficient and a quantum yield of the fluorophore, of Alexa
Fluor 555 and ATTO 550 are 15,000 and 96,000, respec-
tively [37]. Using GenePix 4000B image scanner and iden-
tical experimental conditions, the brightness of ATTO 550
is at least as high as to that of Alexa Fluor 555. Combina-
tions of four spotting buffers, PBS, PBST, TS and SB and
three washing buffers, PBS, PBST and SB were examined
for in situ purification of FolE and LacI. Based upon the
estimation of the relative purity levels of FolE and LacI,
PBST delivered the best results as a spotting and wash
Relative Purity
FAlexa 555 (anti-His-tag)
FAlexa 555 (anti-
=
H His-tag) F ATTO 550 (anti-E.coli) +
.
(1)
Optimization of in situ protein purification Figure 2
Optimization of in situ protein purification. (A) His-tagged FolE and (B) His-tagged Lac repressor. Relative purities of in 
situ purified proteins were determined using the ratio of fluorescence signals of recombinant proteins versus the fluorescence 
signals of total protein, as shown in Equation 1 (see text). White and gray bars represent Cu2+/IDA/PEG slides and non-PEG 
coated Ni2+/NTA slides, respectively. A series of spotting buffers were examined: PBST [10 mM phosphate buffer, 2.7 mM KCl, 
140 mM NaCl, 0.05% Tween 20, pH 7.4], PBS [10 mM phosphate buffer, 154 mM NaCl, pH 7.4], TS [50 mM Tris, 300 mM 
NaCl, 10 mM imidazole, pH 7.8] and SB [100 mM sodium borate, pH 7.8].
0
20
40
60
80
100
PBS PBST TS SB
Spotting buffers
R
e
l
a
t
i
v
e
p
u
r
i
t
y
(
%
)
0
20
40
60
80
100
PBS PBST TS SB
Spotting buffers
R
e
l
a
t
i
v
e
p
u
r
i
t
y
(
%
) A. B. Cu /IDA/PEG 2+
Ni2+/NTA
Cu /IDA/PEG 2+
Ni /NTA 2+BMC Biotechnology 2009, 9:72 http://www.biomedcentral.com/1472-6750/9/72
Page 5 of 10
(page number not for citation purposes)
buffer for both Cu2+/IDA/PEG and Ni2+/NTA slides. In
Figure 2, relative purities of FolE and LacI, printed with
four spotting buffers on both slide surfaces and washed
with PBST, were compared. The relative purities of FolE
with two spotting buffers, PBS and PBST were similar but
the relative purity of Lac I with PBST spotting buffer was
nearly 20% higher than that with PBS. Apparently, the
nonionic detergent Tween-20 mediates partial denatura-
tion of recombinant proteins and enhances the exposure
of His-tags to the Cu2+ or Ni2+ on the slides. This effect
may also increase competitive binding of recombinant
proteins to histidine-rich contaminant E. coli proteins.
The binding and purification characteristics of the two
slide supports, Cu2+/IDA/PEG and Ni2+/NTA, were evalu-
ated using relative purity levels of LacI and FolE (Figure
2). Relative purities of LacI and FolE with PBST were
approximately 80% and 85%, respectively, on the Cu2+/
IDA/PEG slide, and approximately 35% and 75%, respec-
tively, on the Ni2+/NTA slides. His-tagged FolE purified
with higher relative purity than the recombinant LacI on
both slides. Interestingly, relative purities of proteins
using the in situ purification method were correlated to
the quantities of the corresponding solubly expressed pro-
teins in the E. coli cell lysate. His-tagged FolE expressed
solubly at approximately 4.5-fold greater abundance than
His-tagged LacI. The difference in relative purity levels of
the two recombinant proteins was much greater on the
Ni2+/NTA slide (45%) than on the Cu2+/IDA/PEG slide
(10%). Apparently, non-specific protein adsorption on
the slide surface reduced the purity level. Lower non-spe-
cific protein adsorption resulted in less variation in
immobilized protein purity. This finding indicates that
the consistency of in situ purification of proteins is
dependent not only on the surface chemistry of the slide
but also on the quantity of the solubly expressed recom-
binant proteins. It is clear that purity and consistency of in
situ purification using Cu2+/IDA/PEG slides are superior
to that using Ni2+/NTA chelated slides.
The performance of both slide supports was also evalu-
ated with purified LacI as well as FolE and LacI in the E.
coli lysate supernatants. The immobilization of purified
LacI on the slides is not interfered by E. coli endogenous
proteins. We determined that the same relative purity lev-
els were achieved with pre-purified LacI compared to
unpurified LacI, independent of the slide support. How-
ever, the fluorescence intensity for the immobilized LacI
on the Cu2+/IDA/PEG was about 1.9-fold greater than that
on the Ni2+ slide. When E. coli lysate containing overex-
pressed recombinant proteins, either FolE or LacI, was
applied on the slides, non-specific immobilization of E.
coli endogenous proteins on Ni2+/NTA was at least 3-fold
more than on Cu2+/IDA/PEG. Lower capacity of the Ni2+/
NTA slides could be an effect of reduced affinity, density
of reactive groups on slide surface or less accessibility of
His-tag by the antibody. The much higher nonspecific
interactions of Ni2+/NTA resulted from a difference in the
support chemistry and lack of PEG coating. Since the
lower fluorescence signal for purified LacI on the Ni2+/
NTA compared to the Cu2+/IDA/PEG was observed, the
much lower E. coli endogenous signal on Cu2+/IDA/PEG
is more likely due to the PEG coating which has been
reported and used to prevent nonspecific interactions [38-
40].
Both slide types were further examined with 90 recom-
binant S. pneumoniae proteins present in E. coli cell lysates
in varying concentrations. As shown in Figure 3b and 3d,
E. coli endogenous proteins were frequently visualized as
contaminants on the Ni2+/NTA slide surface, but rarely on
the Cu2+/IDA/PEG slide surface. Differences in Alexa
Fluor 555 conjugated anti-His-tag antibody signal intensi-
ties (Figure 3a and 3c) suggest that the slide surface
strongly influenced the efficiency of immobilization of
His-tagged proteins. The fluorescence intensities repre-
senting protein concentrations (FHis-tag) varied considera-
bly among the 90 S. pneumonia proteins (Additional file
1). In summary, this data supported the conclusions
made based on the data with LacI and FolE. The Cu2+/
IDA/PEG is technically clearly superior to the Ni2+/NTA.
Purification and solubility characteristics of 90 
recombinant S. pneumoniae proteins
Randomly selected 90 S. pneumoniae proteins were catego-
rized as membrane and non-membrane proteins using
HMM, INTERPRO domain searches, GO annotations and
COG analysis, in addition to transmembrane domain
motif searches with TMHMM [41], SOSUI [42] and
HMMTOP [43]. Thirty-three proteins were predicted to be
membrane proteins. An overview of the in situ purifica-
tion of these proteins is provided in Table 1. More than
80% of the non-membrane proteins were purified, and
96% of them were calculated to have a purity level higher
than 90%. Interestingly, nearly 73% of the membrane
proteins were also purified and 79% of them surpassed
the 90% purity level. Membrane protein purification is
known to be challenging. In our previous study using this
protein expression strategy, but a different quantitative
detection system, the S-tag [24], more than 50% of the
membrane proteins were solubly expressed, 60% of
which were purified using a Ni2+/NTA agarose resin.
Although our sample numbers were limited for in situ
purification (33 proteins), a trend towards more effective
membrane protein purification on a slide surface is appar-
ent. A study on in vitro expressed C-terminal GST-tagged
proteins, which were obtained by the nucleic acid pro-
grammable protein array (NAPPA) method, reported a
93% detection level for membrane proteins [9], and sup-
ported our conclusions. The fact that many membraneBMC Biotechnology 2009, 9:72 http://www.biomedcentral.com/1472-6750/9/72
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Application of in situ purified S. pneumoniae proteins to immunoassays Figure 3
Application of in situ purified S. pneumoniae proteins to immunoassays. The overexpressed proteins were manually 
printed at approximately 70% humidity using the MicroCaster manual printing device (Whatman, Florham Park, NJ). Immobi-
lized proteins were in situ purified and quantities were assessed using an Alexa Fluor 555 conjugated anti-His-tag antibody (a, c). 
Small white squares in a) and c) denote the position of the immobilized E. coli Lac repressor (control). The relative purity of 
His-tagged S. pneumoniae proteins was assessed by assays with an anti-E. coli antibody and an ATTO 550 labeled 2nd antibody (b, 
d) which resulted in the detection of endogenous E. coli proteins where His-tagged proteins were impure. The protein micro-
array on the Cu2+/IDA/PEG chip (c, d) was subjected to a detection assay with a rabbit anti-S. pneumoniae antibody followed by 
a 2nd antibody (labeled with ATTO 550) (e) and with a human patient serum followed by a 2nd goat anti IgG antibody (labeled 
with Alexa Fluor 555) (f).
Ni2+
/NTA
Cu2+
/IDA
/PEG
a b
c d
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Cu2+
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proteins have domains exposed at the cell surface, makes
the ability to effectively purify them important in the con-
text of their antigenicity and role as vaccine candidates for
human pathogens.
Identification of immunogenic S. pneumoniae proteins
The protein microarray platform was used for a pilot
project, immunoproteomic analysis of the Gram-negative
bacterial pathogen, S. pneumoniae. Anti-S. pneumoniae
antibodies raised in rabbits using a mixture of nine S.
pneumoniae serotypes as immunogens and an antiserum
of a patient infected with S. pneumoniae serotype IV were
used. The antibodies and antisera were pre-treated with E.
coli cell extracts permitting removal of E. coli protein-reac-
tive antibodies which are known to circulate in most ani-
mal and human sera. Binding affinities of anti-S.
pneumoniae  antibodies to recombinant proteins were
determined using the following equation.
RF in Eq. 2 represents fluorescence intensity ratio of a
labeled secondary antibody that measures the interaction
of anti-S. pneumoniae antibodies with immobilized pro-
teins, to the Alexa Fluor 555 conjugated anti-His-tag anti-
body. The anti-His-tag antibody served as a normalizing
factor to compare antigen recognition activities. This is
useful because different proteins are immobilized in dif-
ferent quantities. Three types of RF values for a rabbit anti-
S. pneumoniae antibody (RAb), a human patient antiserum
(RS1) and a healthy human serum (RS0), are provided in
the Additional file 1. RF values greater than 1 suggested an
interaction between a protein and anti-S. pneumoniae anti-
bodies. A strongly reactive protein in the assay with rabbit
antibodies was the manganese ABC transporter adhesion
lipoprotein (PsaA) (Figure 3e). This lipoprotein is
involved in pathogenicity via its role as a host cell adhe-
sion protein. It is a highly conserved immunogenic pro-
tein among many of the 90 S. pneumoniae serotypes
[44,45]. Data for the human patient antiserum (S1) were
compared to those for a non-infected human serum (S0).
Immunogenicity was defined by RF (>1) mentioned above
and R (>2), a ratio of S1 to S0. In addition to PsaA, the
iron-compound ABC transporter PiuA (SP1872) was also
identified as a strong antigen. PiuA is suggested to bind
extracellular iron and deliver it to the permease of the ABC
transporter. The permease facilitates import of the cation
into the cytoplasm. In S. pneumoniae (TIGR4), 10 proteins
are annotated as iron ABC transporters. Although mecha-
nisms of iron uptake by S. pneumoniae are not well charac-
terized, iron transporters are known to be strong antigens
and required for full virulence [46-48]. PsaA and PiuA are
potential vaccine candidates and potential antigenic
markers for the diagnosis of S. pneumoniae infections.
Both proteins are anchored to the cytoplasmic membrane
and exposed at the surface of S. pneumoniae. This study
sets the stage for expression and immunogenic analyses of
a larger number of ABC transporters and other cell sur-
face-localized proteins, testing a large number of human
patient sera. Another interesting application is the design
of a microarray chip displaying a range of antigens recog-
nized at various time points during an infection with S.
pneumoniae and convalescence of the patient.
Conclusion
To our knowledge, this is the first report describing a semi-
quantitative strategy for the measurement of relative pro-
tein purities immobilized in situ on protein microarrays. A
combination of antibodies, one measuring the target pro-
tein (a His-tagged recombinant protein), the other meas-
uring the contamination level with endogenous E. coli
proteins, was used. The strategy we employed has poten-
tial to become a new gold standard for high quality pro-
tein microarrays. We demonstrate that Cu2+/IDA/PEG
successfully reduced non-specific adsorption of proteins
on the substrate. Finally, we demonstrate that this protein
microarray is useful for the discovery of immunogenic
proteins of a bacterium that causes serious infections in
humans.
Methods
Cloning and transformation
From the genome-wide cloning set of Streptococcus pneu-
moniae, TIGR4, previously described [24], 90 ORFs repre-
senting a variety of expression levels were selected for this
R
FATTO 550 (anti-S.pneumoniae)
FAlexa 555 (anti-His-tag)
F = (2)
Table 1: Summary of success frequencies and purities of the in situ purification of 90 recombinant S. pneumoniae proteins.
Protein class Number of proteins Purification (%) >90% relative purity (%) <90% relative purity (%)
Membrane 33 24 (72.7%) 19 (57.6%) 5 (15.2%)
Non-membrane 57 49 (86.0%) 47 (82.5%) 2 (3.5%)
Total 90 73 (81.1%) 66 (73.3%) 7 (7.8%)
Immobilized His-tagged proteins and E. coli endogenous proteins were detected using an Alexa Fluor 555 fluorophore conjugated anti-His-tag 
antibody, and rabbit anti-E. coli antibody followed by incubation with ATTO 550 conjugated goat anti-rabbit antibody. The relative purity was 
calculated using the Equation 1 (text).BMC Biotechnology 2009, 9:72 http://www.biomedcentral.com/1472-6750/9/72
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study. Clones of the ORFs into pET-DEST-TIGR02 (T02)
expression vector were transformed into BLR(DE3) cells
(EMD Biosciences, San Diego, CA) using heat shock
method. Transformants were plated on divided Q-trays
containing 2xYT agar with 100 g/mL ampicillin, 15 g/
mL tetracycline, 0.8% glucose and incubated at 37°C
overnight. A single colony for each clone was picked into
a deep well block containing 1 mL 2xYT, 100 g/mL amp-
icillin, 15 g/mL tetracycline, 0.8% glucose in each well.
The deep well block was grown at 37°C in multitron
shaker at 800 RPM until reaching OD600 0.7–0.9. The cul-
tures were aliquoted to new microtiter plates and glycerol
was added to 10% final concentration. The prepared fro-
zen cultures were stored at -80°C.
Protein overexpression
Cultures for overexpression were set in a 2 mL deep well
block with 1 mL 2xYT broth containing 100 g/mL ampi-
cillin, 15 g/mL tetracycline and 0.8% glucose. After inoc-
ulating with 20 L frozen culture, the cultures were
incubated at 37°C in a multitron shaker at 800 RPM until
OD600 reached 0.7–0.9. Overexpression was induced by
adding 10 L freshly prepared 100 mM IPTG and plates
were incubated overnight at 25°C, 800 RPM. After 18
hours incubation, 50 L of culture were aliquoted to sev-
eral microtiter plates. Cells were pelleted at 3,000 g for 5
min. The waste media was poured off and the pellets were
stored at -80°C until ready for lysis.
Lysis and S-tag assay
The frozen cell pellets were thawed on ice and resus-
pended in the 50 L master mix of lysis buffer [50 mM
Tris, 300 mM NaCl, 10 mM imidazole, 1 mM DTT pH 7.8
at 4°C] and Popculture and lysonase (EMD-Novagen).
After complete resuspension of the cell pellets mixed by
pipette, the plate was shaken at room temperature for 15
minutes to complete lysis. The supernatant of lysate was
separated at 2,000 g for 20 minutes and transfer to a new
96-well plate. The quantities of recombinant proteins in
the supernant were evaluated semi-quantitatively using S-
tag assay as described previously [24].
Printing and washing
Two slides, Ni2+ chelated (Xenopore Corp., Hawthorne,
NJ) and Cu2+ chelated (MicroSurfaces, Inc., Minneapolis,
MN) surface slides were examined. The slides were incu-
bated in a room temperature humidity chamber for thirty
minutes prior to printing. The lysate supernatants were
diluted 1:20 in printing buffers. Slides were manually
printed at ~70% humidity using the MicroCaster manual
printing device (Whatman, Florham Park, NJ). Each
supernatant was printed in triplicate on a single slide
along with supernatant obtained from BLR(DE3) without
expression clones for negative control. After printing,
spots were allowed to dry at ~70% humidity. Combina-
tions of a printing buffers PBST [10 mM phosphate buffer,
2.7 mM KCl, 140 mM NaCl, 0.05% Tween 20, pH 7.4],
PBS [10 mM phosphate buffer, 154 mM NaCl, pH 7.4], TS
[50 mM Tris, 300 mM NaCl, 10 mM imidazole, pH 7.8]
and SB [300 mM sodium borate,, pH 7.8] and washing
buffers: PBST, PBS and SB, were examined with E. coli
superanatant containing recombinantly expressed FolE
and Lac repressor. After evaluating, PBST was used for
printing and washing steps in situ purification of 90 His-
tagged proteins in S. pneumoniae.
Protein microarray with antibody and antiserum
The printed slides were placed in Fast Frame incubation
chambers (Whatman, Florham Park, New Jersey) and
blocked with PBS, 5 mM imidazole pH 7.4, 3% dry milk,
for 1 hour. The blocking solution was drawn off and slides
were washed three times with 2 mL milliQ water each
time. The immobilized recombinant proteins were visual-
ized and quantified by reaction with 200 ng/mL Alexa
Fluor 555 labeled Penta-His antibody in PBS (Qiagen,
Valencia, CA). After 1 hour incubation, the slide was
washed twice with fresh washing buffer (PBST) and rinse
with milliQ water. The protein chip was subject to rabbit
anti-E. coli antibody (Meridian Life Science, Inc., Saco,
ME) and goat anti-rabbit antibody labeled with ATTO 550
to detect of contamination of E. coli endogenous proteins
after purification. The chip was also applied to anti-S.
pneumoniae rabbit antibody (Meridian Life Science, Inc.,
Saco, ME) and human patient antiserum. The rabbit anti-
body was diluted to a final concentration of 1.6 g/mL in
PBS and applied on the protein chip. After incubation for
1 hour, the chip was washed three times with washing
buffer. ATTO 550 labeled anti-rabbit goat antibody was
diluted 1:1000 in 1 mL PBS was applied on the slide in
and incubated at room temperature in the dark for 1 hour.
The slide was washed as described for Penta-His antibody
reaction. Human patient serum was prepared 1:250 dilu-
tion in PBS. The reaction procedure was identical to anti-
S. pneumoiae antibody reaction except using 1 L Alexa
Fluor 555 labeled anti-human IgG goat antibody. The
slides were washed twice with fresh washing buffer and
rinse with milliQ water. The slide was scanned using a
GenePix4000B (Molecular Devices, Sunnyvale, CA). A
GenePix laser of 532 nm and an emission filter of 557–
592 nm were used to obtain fluorescence image.
All antibodies except anti-E. coli antibody and antiserum
were treated with E. coli cell lysate to eliminate anti-E. coli
antibody. A 1 mL BLR(DE3) cell pellet was lysed with 100
uL sodium phosphate lysis solution at room temperature
for 15 minutes. Five microliters of whole BLR(DE3) lysate
was added to the diluted primary and secondary antibody
and incubated at room temperature for 30 minutes. The
cell debris was pelleted at 2,000 × g for 20 minutes. TheBMC Biotechnology 2009, 9:72 http://www.biomedcentral.com/1472-6750/9/72
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supernatants were transferred to a new microfuge tube for
immunoassays.
Analysis
All images were analyzed using Spotfinder. http://
www.jcvi.org/cms/research/software/#c622.
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